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ABSTRACT 
Background: To improve up-titration of medications to target dose in heart failure patients by 
improving communication from hospital to primary care. 
 
Methods: This quality improvement project was undertaken within three heart failure disease 
management (HFDM) services in Queensland, Australia. A structured medication plan was 
collaboratively designed and implemented in an iterative manner, using methods including 
awareness raising and education, audit and feedback, integration into existing work practice, 
and incentive payments. Evaluation was undertaken using sequential audits, and included 
process measures (use of the titration plan, assignment of responsibility) and outcome 
measures (proportion of patients achieving target dose) in HFDM service patients with 
reduced left ventricular ejection fraction. 
 
Results: Comparison of the three patient cohorts (pre-intervention cohort A n=96, 
intervention cohort B n=95, intervention cohort C n=89) showed increase use of the titration 
plan, a shift to greater primary care responsibility for titration, and an increase in the 
proportion of patients achieving target doses of angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers (ACEI/ARB) (A 37% vs B 48% vs C 55%, p=0.051) 
and beta-blockers (A 38% vs B 33% vs C 51%, p=0.045).  Combining all three cohorts, 
patients not on target doses when discharged from hospital were more likely to achieve target 
doses of ACEI/ARB (p<0.0001) and beta blockers (p<0.0001) within six months if they 
received a medication titration plan. 
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Conclusions: A medication titration plan was successfully implemented in three HFDM 
services and improved transitional communication and achievement of target doses of 
evidence-based therapies within six months of hospital discharge.  
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INTRODUCTION 
 Heart failure (HF) is a major public health problem associated with significant 
morbidity and mortality.(1)  Large randomized controlled trials have demonstrated that 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) and 
beta blockers decrease hospitalization and prolong survival in patients with HF with reduced 
left ventricular ejection fraction (HFrEF). However, these therapies can be difficult to 
manage in real-world clinical practice as HF patients frequently transition between acute 
hospital and primary healthcare sectors, and are often older and more complex than patients 
enrolled in the randomized controlled studies.(2)  Nonetheless, suboptimal treatment is 
responsible for a substantial proportion of avoidable re-hospitalizations and deaths.(3) 
 
Whilst several studies have reported that only a small proportion of HFrEF patients are 
on target doses of ACEI/ARB and beta blockers at the time of hospital discharge,(3, 4) this 
may not be a true reflection of the final doses achieved, given that these drugs may require 
careful up-titration over several months.(5)  However, a single-center audit of post-discharge 
titration of heart failure medications in our health service had previously identified that only 
13% of patients achieved target doses at three months (unpublished data).  This is similar to 
other reports of 17 to 43 % of patients achieving target doses within three to six months of 
hospital discharge.(6-9)  This “titration gap” is partly explained by higher rates of drug 
intolerance in unselected, older patients with multiple comorbidities who are under-
represented in clinical trials,(5) but may also represent an opportunity to improve adherence 
to evidence-based treatment in HF. 
 
 Barriers to guideline adherence include context-specific factors impacting upon 
provider knowledge, attitudes and behaviors, such as lack of awareness, lack of familiarity, 
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lack of self-efficacy, inertia, patient expectations, and inadequate time or resources.(10-12)  
Interventions to improve prescribing behaviors have mostly focused on provider knowledge 
and attitudes. Although interventions such as education, point-of-care decision support and 
profiling with feedback have been associated with systematic improvements in some time 
series studies,(9) other studies of this approach have been disappointing.(13)  
 
 In the context of transition from hospital-based to primary care, communication of 
current therapy and expected treatment plans appears to be a major barrier and large registry 
studies confirm that discharge communication for HF patients is poor.(9)  Heart failure 
disease management (HFDM) programs improve outcomes in patients recently discharged 
from hospital, helping to provide a “bridge” between hospital and primary care.(14)  
Specialized HF medical clinics or protocol-driven nurse and pharmacist led clinics can be 
effective in improving titration following hospitalization (15-18) although this finding has not 
been universal.(6)  HFDM services may help to address barriers by providing access to 
specialized multidisciplinary staff familiar with current guidelines, who have the time and 
skills to support medication monitoring. However access to these services remains 
limited(19) and the general practitioner (GP) usually remains the key provider. Clear 
communication between the HFDM service, specialty services and GPs may help to improve 
GP familiarity and confidence with prescribing, as well as set consistent patient and provider 
expectations.  
 
We undertook a quality improvement project to enhance discharge communication 
between the hospital and primary care in order to improve the titration of ACEI/ARB and 
beta blockers following discharge from hospital with a primary diagnosis of HFrEF.  Our 
primary goal was to embed an individualized HF medication titration plan (using a 
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standardized form) into clinical practice. The medication titration form included the discharge 
and recommended target dose of ACEI/ARB and beta blockers, the order of titration, and the 
primary clinician responsible for managing titration. We hypothesized that improved 
communication between healthcare providers would result in a higher proportion of HFrEF 
patients achieving target doses of medications by six months following hospital discharge. 
We report our findings using the SQUIRE guidelines for quality improvement research. 
 
METHODS 
Setting 
Metro North Hospital and Health Service (MNHHS) is the largest publicly funded health 
service in Australia servicing approximately 900,000 people in South East Queensland. We 
undertook the study in three hospitals that have established HFDM teams and together care 
for 80% of HF hospitalizations within MNHHS. Two of the hospitals are large teaching 
hospitals (one with an advanced HF transplant service) and the third is a district hospital 
servicing a rapidly growing population on the urban fringe of Brisbane. The HFDM services 
include expert HF nurses, clinical pharmacists and physiotherapists, and specialist medical 
supervision of the programs. The services provide active case finding throughout the hospital 
with an opt-out approach; patient and carer education continuing post hospitalization; 
discharge coordination between the inpatient treating team, the GP and primary care services; 
and multidisciplinary clinic and/or telephone-based follow-up. About 20 % of patients attend 
a structured weekly group education and exercise program.  None of the services offer home 
visits. Medical follow-up may include HF, general cardiology or medical outpatient clinics 
depending on local resources and patient preferences.  
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The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected 
in a priori approval by the Human Research Ethics Committee (HREC) for all three hospitals 
which reviewed the study protocol and deemed it exempt from ethical review.   
 
Planning the intervention 
The project was supported by a steering committee and three clinical working groups. 
The steering committee consisted of two cardiologists, a general physician, two GPs, a 
pharmacist, a community HF nurse practitioner, and two community-based general nurses. 
The committee met quarterly to provide strategic advice and planning.  The implementation 
group consisted of a senior project manager, clinical working groups of nurses, pharmacists 
and medical leads associated with HFDM services at each participating hospital, and 
representatives of information technology services in the hospital and primary care, who met 
as required to refine and implement intervention strategies.   
 
Interventions were introduced and refined in a quality improvement Plan, Do, Study, 
Act (PDSA) cycle. The interventions centered on supporting the use of a HF medication 
titration plan and methods to embed the titration plan into standard clinical practice including 
performance feedback to HFDM services, ensuring timely communication of the titration 
plan to the GP following discharge from hospital, investigating electronic methods of 
transferring discharge information, considering the use of case-conferencing, and providing 
incentive payments.  
 
Medication titration plan 
Prior to the study, a workgroup including nursing, pharmacy, cardiology and general 
medical representatives had developed and piloted an individualized written HF medication 
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titration plan using a standardized form.  Modifications were made following input from renal 
and respiratory medical specialists (see HF Medication Titration Plan, figure 1). This 
document detailed ACEI/ARB and beta blocker therapy on discharge with clear instructions 
regarding the order and extent of titration of these medications. Instructions for weight-based 
diuretic titration were provided if appropriate. The document allowed clear delegation of the 
primary person responsible for titration (hospital specialist, HFDM nurse, or GP) and 
provided a troubleshooting guide. The primary person was negotiated by the heart failure 
disease management staff in discussion with the patient and in collaboration with the treating 
hospital team and general practitioner, influenced by practical and clinical considerations 
including clinical complexity, physical access to services, patient preference, and provider 
confidence. Patients had the option to choose to see their general practitioner to supervise 
medication titration. In these cases, the general practitioner was contacted by the heart failure 
nurse to confirm that they were happy to supervise titration. The medication titration plan 
addressed several potential barriers by providing individualized point-of-care decision 
support; setting clear expectations which could be developed in collaboration with the 
patient; providing access to a specialist service if time or skills were a barrier to titration; and 
providing single point accountability. Although the medication titration plan was available, it 
was inconsistently used prior to the project.  
 
This improvement project aimed to embed the use of the HF medication titration plan 
into routine clinical practice with the goal of improving medication titration for patients with 
HF in the community.  Specifically, it aimed to improve post-discharge communication of a 
titration plan, provide clearer accountability for titration, and thereby increase achievement of 
optimal dosing of ACEI/ARB and beta blockers by six months after hospital discharge. 
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Implementation of titration plan 
Barriers and potential solutions were developed by interviewing GP’s and practice 
managers of patients attending HF services in MNHHS as well as consulting with hospital-
based implementation groups.  These are summarized in Table 1 along with the actions 
agreed to by the project steering committee.  
 
Planning the evaluation 
Design and patient characteristics 
To evaluate the effect of the intervention, we conducted three audits of consecutive, 
eligible patients with HFrEF discharged from the study hospitals between July to December 
2009 (Cohort A, pre-intervention), 2010 (Cohort B) and 2011 (Cohort C). Recruitment of 
patients for all groups was at the same time of year to minimize the influence of seasonal 
variation. The baseline audit (Cohort A) was retrospective and the two intervention groups 
(Cohorts B and C) were prospective.  
 
Eligibility criteria were patients newly referred to the hospital-based HFDM services 
following an admission to hospital with a primary diagnosis of HFrEF, with a left ventricular 
ejection fraction (LVEF) <50%, who were then followed up in the MNHHS and had no 
documented contraindication to medication titration or palliative intent to treatment.  Given 
that the aim of this study was to evaluate titration of medical therapy over six-months, 
patients were excluded if they could not be contacted or died during the follow-up period. 
 
Measures and outcomes 
Patient characteristics, prescription and doses of HF medications at hospital discharge 
and six months, and quality of medication titration information communicated was collected 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
1/09/2016 11 
from hospital charts, HFDM service notes, electronic discharge summaries, and electronic 
databases, supplemented if necessary by telephone interviews of patients, their GPs or GP 
practice managers. Data were collected by an experienced project manager not involved in 
delivery of services. 
 
The primary endpoint was the proportion of patients who were on target doses of either 
ACEI/ARB or beta blockers at six months following discharge from hospital. Target doses 
were those defined in the major clinical trials that demonstrated the mortality and morbidity 
benefit for these treatments and reported in therapeutic guidelines.(20) A secondary endpoint 
limited the analysis to those patients who were not receiving target doses of either 
ACEI/ARB or beta blockers at the time of hospital discharge.  Additional, pre-specified 
endpoints were the proportion of patients who received a HF medication titration plan, and 
the proportion of patients where there was clear identification of the primary clinician 
responsible for medication titration. An additional exploratory analysis combined all three 
cohorts to identify whether completion of a titration plan was associated with greater 
achievement of target dose. 
 
Analysis 
The proportion of participants achieving each of the pre-specified outcomes was 
compared between the three groups using Chi-squared tests, or Fisher’s exact tests when the 
expected cell counts were low. In the exploratory analysis of all cohorts combined, we sought 
associations between the use of the titration plan and target dose achievement at six months, 
as well as exploring other potential factors influencing successful titration, using chi-square 
testing.(21) We undertook multivariable logistic regression and adjusted for age, hospital and 
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cohort to identify any variables that may be predictors of target dose achievement.  Statistical 
significance was considered as p<0.05 in all analyses.  
 
RESULTS 
 
Improvement interventions 
Initial planning commenced in 2009, and the program was launched in 2010. Results 
from the retrospective audit of usual care (Cohort A) were summarized and fed back to the 
clinical workgroups and to GPs. One-hour interactive workshops were delivered to each of 
the HFDM teams to refresh knowledge about the medication titration content, clarify that 
they would take primary responsibility for completion, and discussing their role in 
negotiating with the patient/carer, hospital staff and GP about continuing titration 
responsibilities. Information about the medication titration plan was sent to GPs through their 
network newsletter, which included contact details for the project leader. Further feedback 
though local networks was provided in 2011 following the second audit, and included contact 
details for key staff within the HFDM services for GPs to be able to contact if required.  
 
Attempts at using electronic transmission had limited success. We designed a macro 
that could be embedded within the electronic discharge summary; however this was only 
used eight times (seven times for Cohort B, once in Cohort C). The main barrier to the use of 
the macro was the coordination required between the HFDM nurses and junior medical staff 
in finalizing the electronic discharge summary. Secure, web-based emailing was technically 
complex making it difficult for hospitals to use and GP’s to access. The health record 
exchange (a record initiated by primary care with the permission of the patient) was rarely 
accessed by clinicians as most patients were not registered, and there were delays in software 
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installation. Therefore, completion of the medication titration plan as a stand-alone document 
with fax following hospital discharge was the primary mode of transmission utilized between 
the HFDM services and the GP. 
 
While substantial planning was undertaken to facilitate use of the Medicare chronic 
disease billing process, coordination of the eligibility requirements and hospital and GP staff 
was too challenging in practice within existing resources, and was abandoned in the first six 
months as there had been no uptake. In 2011, the steering committee members on the 
statewide cardiac clinical network successfully advocated for state government quality 
incentive payments to support implementation of the titration plan. This provided a direct 
payment of $150 to all HFDM services in Queensland (including the three HFDM services 
involved in this study) for each titration plan completed, for use on clinical services and/or 
education.  
 
Study sample 
The flow of patient recruitment for each study group is shown in Table 2. Of the 335 
patients who met eligibility criteria, 9.9 % died and 6.6 % were lost to follow-up at six 
months post-hospital discharge.  The final analysis included the 280 patients who survived 
and had six-month follow-up data on medication titration status. Of this cohort, 98% were 
eligible to take ACEI/ARB and 96% were eligible for beta blockers. Six-month follow-up 
data were missing in a greater proportion of patients in the retrospective cohort (Cohort A).  
 
The patient characteristics for the three study cohorts are described in Table 3. Groups 
were similar for age, sex, hospital length of stay, LVEF and number of comorbidities (which 
included any chronic medical condition such as peripheral neuropathy, diabetes, 
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hypertension, ischemic heart disease, gastro-esophageal reflux disease, gout, and depression).  
The number of medications prescribed and the use of Webster packs (weekly pharmacy 
packed blister packs) were similar for all three cohorts. There were similar rates of 
prescription, which were high with over 95% of patients prescribed an ACEI/ARB and over 
90% of patients prescribed a beta blocker at the time of hospital discharge. 
 
Impact of interventions on processes and outcomes 
The proportion of participants who had a titration plan completed at hospital discharge 
increased throughout the study (Cohort A 26%, Cohort B 45%, Cohort C 61%, p<0.001). 
There was also a significant change (p<0.001) in the pattern of clinicians identified as 
responsible for titration in the plan (Figure 2), with an increase in those for whom the GP was 
responsible (Cohort A 27%, Cohort B 35%, Cohort C 49%) and a decrease in those for whom 
the specialist was responsible (Cohort A 18%, Cohort B 24%, Cohort C 2.8%) or no 
responsible clinician was identified.  
 
 At six months post hospital discharge, the proportions of eligible patients receiving an 
ACEI/ARB for Cohorts A, B and C respectively were  87/94 (93%), 90/94 (96%), and 81/85 
(95%). Beta blocker prescription rates were 89/93 (96%), 89/90 (99%), and 82/84 (98%). The 
proportion of all eligible patients who achieved target doses six months after discharge for 
ACEI/ARB (37% vs. 48% vs. 55%, p=0.051) and beta blockers (38% vs. 33% vs. 51%, 
P=0.045) increased throughout the study period (see Table 4).  Whilst this was partly 
accounted for by better achievement of target doses at hospital discharge throughout the 
study period (ACEI/ARB: 26/94 (28.0%); 29/94 (30.9%); 34/85 (40.0%) and beta blockers: 
14/93 (15.1%); 11/90 (12.3%); 19/84 (22.6%)), the improvements in achieving target dose 
were still seen if the analysis was restricted to those patients who were not on target doses at 
the time of hospital discharge (Table 4). 
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Combining participants from all three cohorts, those who received a medication 
titration plan were more likely to achieve target doses of ACEI/ARB (54% vs 34%, p=0.001) 
and beta blockers (54% vs 38%, p=0.013). Restricting the analysis to patients who were not 
on target doses at the time of hospital discharge, those who received a medication titration 
plan were much more likely to achieve target doses of ACEI/ARB (49% vs 21%, p<0.0001) 
and beta blockers (46% vs 20%, p<0.0001).  
 
To identify factors associated with not taking target doses of medication, we undertook 
an analysis combining patients in all three cohorts. Patients who were not taking target doses 
of ACEI/ARB at the completion of the study were older (71.6+14.6 vs. 66.5+13.9 yrs, 
P=0.004) and were less likely to have received a medication titration plan (33.6% vs. 54.3%, 
P=0.029). Patients who were not taking target doses of beta blockers were older (71.7+13.7 
vs. 65.8+14.6 yrs, P=0.001), had a lower discharge weight (75.8+20.6 vs. 83.3+21.3 kg, 
P=0.011), had more comorbidities (5 (IQR 3-6) vs. 4 (IQR 2-6), P=0.022), and were less 
likely to have received a medication titration plan (38.4% vs. 53.7%, P=0.013). Logistic 
regression models were corrected for age, hospital and cohort. Older age (P=0.01) and not 
receiving a medication titration plan (P=0.015) were independent predictors for not taking 
target doses of ACEI/ARB, and older age (P=0.013) was an independent predictor for not 
taking target doses of beta blockers.  
 
 
DISCUSSION 
We undertook a quality improvement project in the setting of three established HFDM 
services to improve communication between hospital-based and primary healthcare 
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providers, in order to enhance the titration of medical therapy in patients following discharge 
from hospital with a primary diagnosis of HFrEF. The main quality improvement tool was a 
HF medication titration plan completed by HFDM staff that provided individualized point-of-
care decision support and explicitly assigned responsibility for post-hospital medication 
titration. Implementation was facilitated by awareness raising through audit and feedback, 
targeted HFDM staff training, incorporation into existing work flows, and in the final cohort, 
financial incentives. Increased uptake of the medication titration plan was demonstrated in 
serial audits, and was associated with significant improvements in achieving target doses of 
evidence-based therapies at six months post-hospital discharge. A combined cohort analysis 
demonstrated that the use of the titration plan was associated with a higher proportion of 
patients achieving target doses. 
 
Despite promising developments in information technology solutions to improve 
communication, technical and work flow complexity made these solutions impracticable. The 
limited utility of electronic processes to improve quality measures has been identified by 
others, with system and recipient issues that may impede successful implementation.(22) We 
therefore reverted to a faxed paper record to allow timely communication of the medication 
titration plan to the GP following hospital discharge.  
 
Financial incentives had variable impact.  Few GPs took advantage of the Medicare 
case conferencing reimbursement which was most likely related to the complexity in meeting 
Medicare billing requirements as previously described by others.(23)  However, financial 
incentives provided to HFDM staff for facilitating medication titration form completion may 
have contributed to the continued improvement in uptake and outcomes in Cohort C 
compared to Cohort B.   
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Relation to other evidence   
 The proportion of patients achieving target doses in this study (55% for ACEI/ARB and 
51% for beta blockers) approach those reported in the clinical trials that demonstrated the 
efficacy of ACEI, ARB and beta blocker therapy conducted in highly selected populations. 
These trials used forced up-titration, with at least 50-60% of patients achieving pre-specified 
target doses.(24-30)  This is encouraging considering the additional support provided in 
clinical trial settings, compared to real world practice.  
 
The demographics of the study sample are similar to patients with HFrEF seen by 
specialized HFDM teams elsewhere in regards to age, sex, and LVEF.(7, 16)  While support 
for medication titration within HFDM services may improve target dose achievement,(15, 16) 
specialized services can better support patients by forming partnerships with primary care 
providers.(11, 31-33)  Our findings complement the results of the Comparative study On 
guideline Adherence and patient Compliance in Heart failure patients (COACH-2) study, 
which demonstrated that patients could be discharged back to their GP following medication 
titration performed in a specialized HF service.(34) They observed similar guideline-
recommended prescription of HF medications at 12 months for patients who were followed 
up by either their GP or in a dedicated HF clinic.(34) Our study suggests that GPs could also 
play a greater role in initial medication titration following discharge from hospital as 
demonstrated by the 20% increase in GPs nominated to manage titration by the end of the 
study, despite this group not directly benefiting from the financial incentives implemented.  
Audit and feedback as provided in this study has been shown to be effective in prescribing 
practice,(32) but is difficult to sustain without  information systems that collect and report 
these data routinely.  Furthermore, audit and feedback alone is unlikely to allow primary care 
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clinicians to follow complicated titration protocols. However, a dedicated medication titration 
plan with trouble-shooting guidelines facilitated by HFDM services was successful in our 
study. The application of incentive payments may have contributed to desirable behavior 
change, however these should be applied selectively to ensure that improvements in practice 
gaps are not accompanied by unanticipated harm. (35, 36) 
 
Application in practice 
Our findings are relevant to other facilities with HFDM services that have a role in 
facilitating communication at the transition of care from the hospital setting to the 
community. Unfortunately, such services are still not widely implemented in Australia.(19)  
Further investigation would be required to determine if the HF medication titration plan could 
be implemented in hospitals lacking such services, as part of their discharge planning. 
Education and training for multiple staff is likely to be a significant barrier in this context, 
and additional support methods such as audit and feedback, incentives and integration into 
work flows need to be carefully considered.  
 
Limitations 
Our study has a number of limitations. Firstly, in the absence of a randomized 
controlled study design, we cannot necessarily attribute the improvement in medication 
titration to the increased utilization of the medication titration plan or the specific strategies 
used. However, we initially evaluated the feasibility of introducing a number of quality 
improvement measures some of which were not successful. This required an adaptive study 
design, which would not have been possible in a randomized controlled study. Whilst the 
retrospective audit in the usual care group (Cohort A) enabled rapid collection of baseline 
data to help inform the development of interventions, it is also probably the reason that a 
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greater number of patients were lost to follow-up at six months. This may have introduced 
bias, although participant characteristics in the three cohorts were similar. This would also 
not explain the greater utilization of medication titration plans and higher titration rates 
achieved in Cohort C compared to Cohort B. 
 
The contribution of the different interventions to enhance use of the medication titration 
plan remains uncertain, as with many successful behavior change interventions, and 
highlights the need for flexible, context-sensitive implementation. Electronic methods of 
transferring discharge information (secure, web-based emailing; health record exchange) 
were not successful and therefore not implemented, with the fax remaining the primary mode 
of transmitting the medication titration plan to the GP. Finally, this was a relatively small 
study and all three hospitals involved in our study had HFDM programs.  Our findings may 
not apply to a more diverse heart failure cohort, or if these services are not available.  
 
Conclusion 
Using a combination of implementation strategies to embed a collaboratively 
developed, structured, HF medication titration plan, we significantly increased use of a 
shared titration plan with clear allocation of responsibility for titration. This was associated 
with a higher proportion of HFrEF patients achieving optimal doses of evidence-based HF 
medications over a three year period. Our findings support interventions that aim to achieve a 
seamless approach to HF care by enhancing collaboration between healthcare providers to 
facilitate transition from the acute hospital setting to the community. The introduction of 
incentive payments was associated with greater uptake of the titration plan, however further 
study is required to determine whether these benefits were maintained. 
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Figure legend 
 
Figure 1: Heart Failure Medication Titration Plan 
 
Figure 2: Changes in documented responsible clinician for titration
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Table 1: Barriers to titration plan use and proposed solutions 
 
Barrier Proposed solution Proposed action 
Unclear guidelines 
for use of titration 
plan 
Steering committee articulated 
clear requirement for all 
discharged  HF patients to 
have a medication titration 
plan communicated to GP 
within 2 weeks of discharge, 
regardless of principal place of 
follow-up 
 
 Clinical working groups provide education 
and training to all HFDM staff 
 Clinical leads provide information to 
inpatient teams 
 Implementation team distribute newsletter 
to primary care for awareness raising  
Confusion between 
health teams about 
responsibility for 
medication titration  
 
Titration plan must state 
which health professional is 
expected to be the primary 
manager of titration post 
hospital discharge 
Train HFDM staff to ensure specification of 
medication titration manager on titration plan 
Changing junior 
medical staff with 
high training 
requirement 
Primary responsibility for 
completing plan remains with 
HFDM staff who are 
consistent, interfacing with 
junior medical staff as 
required 
 
Clinical working groups provide education and 
training to all HFDM staff on tool completion 
and methods of transmission of information 
Competing tasks and 
priorities in HFDM 
service 
Provide feedback on 
performance and incentives 
 Implementation team provide annual audit 
and feedback 
 Quality incentive payment from state 
government  of $150  paid to HFDM 
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service (Cohort C only) 
 
Poor interface with 
existing primary care 
IT systems 
Integrate with existing 
hospital electronic discharge 
summary (EDS) and 
investigate novel methods of 
transmission 
 IT services develop and implement 
“macro” to insert into EDS 
 IT services ensure titration plan 
compatibility with developing primary 
care health record exchange methods 
 HFDM staff trained in use of novel 
systems 
 
GPs have difficulty 
identifying HFDM 
service staff   
Clear identification of HFDM 
service staff 
Contact details for HFDM service staff included 
in annual newsletter and in weekly updates to 
primary care and included on   
 titration plan 
 
Competing tasks and 
priorities in primary 
care 
Reward for collaborating on 
plan development 
Establish processes consistent with Medicare case 
conference for reimbursement (Government 
funded item for team plan with GP and two other 
health professionals) 
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Table 2: Patient flow 
 Cohort A Cohort B Cohort C Total sample 
Patients referred 126 103 106 335 
Died by 6 months 12  7  14  33 
Lost to follow up by 6 months 18 1  3  22  
Included in analysis 96  95  89  280 
a) ACEI/ARB eligible 94 94 85 273 
b) Beta blocker eligible 93 90 84 267 
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Table 3: Characteristics of subjects included in analysis 
Characteristic Cohort A 
 (n=96) 
Cohort B 
 (n=95) 
Cohort C 
 (n=89) 
Age, mean (SD)  68.4 (15.6) 70.4 (13.4) 69.7 (14.4) 
Male  63.5% 63.2% 66.3% 
Length of stay, median (IQR) 7 (4-12) 6 (4-9) 6 (4-10) 
Ejection Fraction, mean (SD) 30.9 (8.3) 32.5 (10.1) 30.7 (9.8) 
Number of medications at D/C, mean (SD)    10.7 (4.1) 9.7 (4.7) 10.7 (4.4) 
Co-morbidities, median (IQR) 5 (3-6) 4 (3-6) 5 (3-6) 
Diabetes  35.4% 27.4% 28.1% 
Hypertension  47.9% 50.5% 55.1% 
Webster Pack  11.5% 16.8% 16.9% 
ACEI/ARB prescribed at discharge  96.9% 99.0% 95.5% 
Beta blocker prescribed at discharge 94.5% 91.6% 94.4% 
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Table 4: Target dose achievement of ACEI/ARB and beta blockers at 6 months after discharge 
Sample Medication Cohort A Cohort B Cohort C p-value 
 All eligible patients ACEI/ARB  35/94 (37%) 45/94 (48%) 47/85 (55%) 0.051 
 Beta-blocker  35/93 (38%) 30/90 (33%) 43/84 (51%) 0.045* 
 Not on target dose on discharge ACEI/ARB  16/68 (24%) 23/65 (35%) 21/51 (41%) 0.11 
 Beta-blocker  23/79 (29%) 20/79 (25%) 29/65 (45%) 0.036* 
*Significant at p<0.05 
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Fig. 1 
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Fig. 2 
 
